Mannitol intravenous
Generic name
Mannitol intravenous
Brand name
ATC Code
B05BC01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
There is no information about the pharmacokinetic parameters for mannitol in children.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Improvement of hemodynamic stability during hemodialysis (HD) |
|---|
|
| Reduction of intracranial or intraocular pressure, acute renal insufficiency |
|---|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Mannitol may accumulate after several doses causing a reverse osmotic effect. The serum osmolality must remain below 320 mOsmol/kg due to the risk of acute renal failure. When administered rapidly there may possibly be a temporary increase in cerebral blood flow (CBF) and intracranial pressure. At low temperatures and particularly at higher concentrations, crystallization can occur; use a 5-micron filter. Monitor for abnormal electrolyte balance and for signs of pulmonary congestion and cardiac failure. Watch out for anuria.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
I.V. SOLUTIONS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Solutions affecting the electrolyte balance | ||
|---|---|---|
| B05BB01 | ||
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen , 2008
- Yanko JR, et al, Acute care management of severe traumatic brain injuries, Crit Care Nurs Q, 2001, Feb;23(4), 1-23; quiz 2 p following 66
- Singhi SC, et al, Management of intracranial hypertension, Indian J Pediatr, 2009, May;76(5), 519-29
- Adelson PD, et al, Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury, Pediatr Crit Care Med, 2003 , Jul;4(3 Suppl):, S40-4
- Knapp JM, Hyperosmolar therapy in the treatment of severe head injury in children: mannitol and hypertonic saline, AACN Clin Issues, 2005, Apr-Jun;16(2), 199-211
- Hothi DK, et al, The value of sequential dialysis, mannitol and midodrine in managing children prone to dialysis failure, Pediatr Nephrol, 2009, Aug;24(8), 1587-91
- Baxter BV, SPC Mannitol (RVG 31795) 28-12-2012, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
